{"id":19813,"date":"2022-03-17T11:29:03","date_gmt":"2022-03-17T11:29:03","guid":{"rendered":"https:\/\/zeepedia.com\/?p=19813"},"modified":"2022-03-19T10:59:59","modified_gmt":"2022-03-19T10:59:59","slug":"ontruzant","status":"publish","type":"post","link":"https:\/\/zeepedia.com\/medical\/medicines\/ontruzant\/","title":{"rendered":"Ontruzant &#8211; Trastuzumab uses, dose and side effects"},"content":{"rendered":"\n<p>Ontruzant 150 mg powder for concentrate for solution for infusion Ontruzant 420 mg powder for concentrate for solution for infusion<br><a href=\"https:\/\/zeepedia.com\/medical\/medicines\/trazimera\/\">trastuzumab<\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">What Ontruzant is and what it is used for<\/h2>\n\n\n\n<p>Ontruzant contains the active substance trastuzumab, which is a monoclonal\u00a0antibody.\u00a0Monoclonal\u00a0antibodies\u00a0are attached to specific\u00a0proteins\u00a0or\u00a0antigens.\u00a0Trastuzumab is designed to bind selectively to an\u00a0antigen\u00a0called\u00a0human\u00a0epidermal\u00a0growth factor receptor 2 (\u00a0HER2\u00a0).\u00a0HER2\u00a0is found in large amounts on the surface of certain cancer cells and then stimulates cell growth.\u00a0When Ontruzant binds to\u00a0HER2, the growth of the cancer cells is stopped and it leads to their death.<\/p>\n\n\n\n<p>Your doctor may prescribe Ontruzant for the treatment of breast and stomach cancer then:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>You have&nbsp;early breast cancer&nbsp;, with high levels of&nbsp;protein&nbsp;et&nbsp;HER2&nbsp;.<\/li><li>You have&nbsp;metastatic breast cancer&nbsp;(breast cancer that spread outside the original&nbsp;tumor&nbsp;) with high levels of&nbsp;HER2&nbsp;.&nbsp;Ontruzant can be prescribed in combination with the&nbsp;cytotoxic&nbsp;drugs paclitaxel or docetaxel as first-line treatment for metastatic breast cancer, or it can be prescribed as the only treatment for conditions where other treatments have not shown effect.&nbsp;It is also used in combination with medicines called aromatase inhibitors for the treatment of patients with high levels of&nbsp;HER2&nbsp;and hormone receptor positive metastatic (spread) breast cancer (cancer that is sensitive to the presence of female sex hormone).<\/li><li>You have&nbsp;metastatic gastric cancer&nbsp;with high levels of&nbsp;HER2&nbsp;, as it is used in combination with capecitabine or 5-fluorouracil and cisplatin.<\/li><\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">What you need to know before you use Ontruzant<\/h2>\n\n\n\n<h2 class=\"wp-block-heading\">Do not use Ontruzant<\/h2>\n\n\n\n<ul class=\"wp-block-list\"><li>if you are allergic to trastuzumab, murine (mouse)&nbsp;protein&nbsp;or any of the other ingredients of this medicine (listed in section 6).<\/li><li>if you have severe breathing problems at rest due to your cancer or if you need oxygen therapy.<\/li><\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Warnings and cautions<\/h2>\n\n\n\n<p>Your doctor will closely monitor your treatment.<\/p>\n\n\n\n<p><strong>Control of the heart<\/strong><\/p>\n\n\n\n<p>Treatment with Ontruzant (alone or with a taxane) can affect the heart, especially if you have previously been treated with an&nbsp;anthracycline&nbsp;(taxanes and&nbsp;anthracyclines&nbsp;are two other types of medicines used to treat cancer).<\/p>\n\n\n\n<p>The effects can be moderate to severe and some patients have died.&nbsp;Your heart function will therefore be checked before and during treatment (every three months) and after (up to two to five years) treatment with Ontruzant.&nbsp;If you develop signs of&nbsp;heart failure&nbsp;(insufficient pumping of blood from the heart), your heart function may be checked more often (every six to eight weeks).&nbsp;You may then receive treatment for&nbsp;heart failure&nbsp;or you may need to discontinue treatment with Ontruzant.<\/p>\n\n\n\n<p>Talk to your doctor, pharmacist, or nurse before receiving Ontruzant about:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>you have had&nbsp;heart failure&nbsp;, coronary heart disease, heart valve disease (&nbsp;wheezing&nbsp;) or high&nbsp;blood pressure&nbsp;, if you have taken or are currently taking medicines for high&nbsp;blood pressure&nbsp;.<\/li><li>you have previously received or are currently receiving a medicine called doxorubicin or epirubicin (a medicine used to treat cancer).&nbsp;These medicines (or other&nbsp;anthracyclines&nbsp;) can damage the heart muscle and increase the risk of heart problems with Ontruzant.<\/li><li>you suffer from shortness of breath, especially if you are treated with a taxane at the same time.&nbsp;Ontruzant can cause breathing difficulties, especially when given for the first time.&nbsp;This can be more serious if you are already short of breath.&nbsp;Patients with severe respiratory distress have in very rare cases died in connection with Ontruzant treatment.<\/li><li>you have previously received any other treatment for cancer.<\/li><\/ul>\n\n\n\n<p>If you are taking Ontruzant with other medicines used to treat cancer, such as paclitaxel, docetaxel, an aromatase inhibitor, capecitabine, 5-fluorouracil, or cisplatin, you should also carefully read the package leaflets for these products.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Children and young people<\/h2>\n\n\n\n<p>Ontruzant is not recommended for anyone under 18 years of age.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Other drugs and Ontruzant<\/h2>\n\n\n\n<p>Tell your doctor, pharmacist, or nurse if you are taking, have recently taken, or might take any other medicines.<\/p>\n\n\n\n<p>It can take up to 7 months for Ontruzant to be removed from the body.\u00a0You should therefore tell your doctor, pharmacist, or nurse that you have been treated with Ontruzant if you start any new medication within 7 months of stopping treatment.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Pregnancy and breastfeeding<\/h2>\n\n\n\n<p><strong>Pregnancy<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor, pharmacist or nurse for advice before taking this medicine.<\/li><li>You should use effective contraception during treatment with Ontruzant and for at least 7 months after stopping treatment.<\/li><li>Your doctor will advise you on the risks and benefits of taking Ontruzant during pregnancy.&nbsp;In rare cases, pregnant women treated with Ontruzant have seen a decrease in the amount of (fetal) fluid that surrounds the growing fetus in the womb.&nbsp;This condition can be harmful to the baby in the womb and has been associated with the lungs not developing fully, resulting in fetal death.<\/li><\/ul>\n\n\n\n<p><strong>Breast-feeding<\/strong><\/p>\n\n\n\n<p>Do not breast-feed your baby during treatment with Ontruzant and within 7 months after the last&nbsp;dose&nbsp;of Ontruzant as Ontruzant may pass to your baby through breast milk.<\/p>\n\n\n\n<p>Ask your doctor or pharmacist for advice before taking any medicine.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Driving and using machines<\/h2>\n\n\n\n<p>Ontruzant may affect your ability to drive or use machines.\u00a0If you develop symptoms such as dizziness, drowsiness, chills, or fever during treatment, you should not drive or use machines until these symptoms have disappeared.<\/p>\n\n\n\n<p><strong>Sodium<\/strong><\/p>\n\n\n\n<p>This medicine contains less than 1 mmol (23 mg)\u00a0sodium\u00a0per\u00a0dose, ie essentially &#8216;sodium-free&#8217;.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">How to use Ontruzant<\/h2>\n\n\n\n<p>Before starting treatment, your doctor will decide if your\u00a0tumor\u00a0is\u00a0HER2\u00a0-positive.\u00a0Only patients with\u00a0HER2\u00a0-positive cancer (large amounts of\u00a0HER2\u00a0) will be treated with Ontruzant.\u00a0Ontruzant should only be given by a doctor or nurse.\u00a0Your doctor will prescribe the right\u00a0dose\u00a0and treatment regimen for\u00a0<em><strong>you<\/strong><\/em>.\u00a0The dose of ontruzant depends on your body weight.<\/p>\n\n\n\n<p>Ontruzant is given as\u00a0an infusion\u00a0into a vein (\u00a0intravenous\u00a0infusion, &#8220;drip&#8221;).\u00a0This intravenous\u00a0preparation\u00a0is not intended for\u00a0subcutaneous\u00a0use and should only be given by\u00a0intravenous\u00a0infusion.<\/p>\n\n\n\n<p>The first&nbsp;dose&nbsp;is given over 90 minutes and you will be observed by healthcare professionals while receiving it in case of any&nbsp;side effects&nbsp;(see section 2 under \u201cWarnings and precautions\u201d).&nbsp;If the first&nbsp;dose&nbsp;is well tolerated, the following&nbsp;dose&nbsp;can be given for 30 minutes.&nbsp;The number of&nbsp;infusions&nbsp;that you receive depends on the effect of the treatment you have.&nbsp;Your doctor will discuss this with you.<\/p>\n\n\n\n<p>To prevent medication errors, it is important to check the label of the vial to ensure that the medicine is prepared and administered is Ontruzant (trastuzumab) and not any other product containing trastuzumab (eg trastuzumab emtansine or trastuzumab deruxtecan).<\/p>\n\n\n\n<p>In early breast cancer, metastatic breast cancer, and metastatic gastric cancer, Ontruzant is given every three weeks.\u00a0Ontruzant can also be given once a week for metastatic breast cancer.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">If you stop using Ontruzant<\/h2>\n\n\n\n<p>Do not stop using this medicine without talking to your doctor first.&nbsp;All&nbsp;doses&nbsp;should be taken at the right time each week or every three weeks (depending on your dosing interval).&nbsp;This helps the drug to work as well as possible.<\/p>\n\n\n\n<p>It can take up to 7 months before Ontruzant disappears from the body.&nbsp;Therefore, your doctor may decide to continue to monitor your heart function even after treatment is stopped.<\/p>\n\n\n\n<p>If you have any further questions on the use of this product, ask your doctor, pharmacist, or nurse.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Possible side effects<\/h2>\n\n\n\n<p>Like all medicines, Ontruzant can cause\u00a0side effects, although not everybody gets them.\u00a0Some of these\u00a0side effects\u00a0can be serious and may involve hospitalization.<\/p>\n\n\n\n<p>During an&nbsp;infusion&nbsp;of Ontruzant<\/p>\n\n\n\n<p>chills, fever, and other\u00a0flu-like symptoms\u00a0may occur.\u00a0These\u00a0side effects\u00a0are very common (may affect more than 1 in 10 people).\u00a0Other symptoms caused by\u00a0infusion\u00a0one are: nausea, vomiting, pain, increased muscle tension and tremors, headache, dizziness, difficulty breathing, high or low\u00a0blood pressure, altered heart rhythm (palpitations, heart flutter, or irregular heartbeat), swelling of the face and lips and lips.\u00a0Some of these symptoms may be severe and some patients have died (see section 2 under \u201cWarnings and precautions\u201d).<\/p>\n\n\n\n<p>These effects occur mainly in connection with the first intravenous\u00a0infusion\u00a0(drip) and during the first hours after the start of\u00a0infusion.\u00a0They are usually temporary.\u00a0You will be monitored by healthcare professionals during\u00a0infusion\u00a0one and for at least six hours after the start of the first\u00a0infusion\u00a0one and two hours after the start of the second\u00a0infusion.\u00a0If you develop symptoms, healthcare professionals will slow down or discontinue the\u00a0infusion\u00a0and they may give you treatment to counteract the\u00a0side effects.\u00a0After improvement of the symptoms, the\u00a0infusion\u00a0can be continued.<\/p>\n\n\n\n<p>Occasionally, symptoms may occur later than six hours after the start of the\u00a0infusion.\u00a0If this happens to you, contact your doctor immediately.\u00a0Sometimes the symptoms can improve and later worsen.<\/p>\n\n\n\n<p><strong>Serious side effects<\/strong><\/p>\n\n\n\n<p>Other\u00a0side effects\u00a0may occur at any time during treatment with Ontruzant and are not associated with the\u00a0infusion\u00a0itself.\u00a0<strong>Tell a doctor or nurse immediately if you notice any of the following side effects:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>Heart problems can sometimes occur during treatment and sometimes after treatment has stopped and can be serious.&nbsp;They include weakening of the heart muscle that can possibly lead to&nbsp;heart failure&nbsp;,&nbsp;inflammation&nbsp;around the heart and altered heart rhythm.&nbsp;This can lead to symptoms such as shortness of breath (including shortness of breath during the night), cough, fluid retention (swelling) in the legs or arms, palpitations (heart flutter or irregular heartbeat) (see section 2. Checking the heart).<\/li><\/ul>\n\n\n\n<p>Your doctor will check your heart regularly during and after treatment, but you should tell your doctor immediately if you experience any of the above symptoms.<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>Tumor light syndrome (group of metabolic complications that occur after cancer treatment and are characterized by high levels of&nbsp;potassium&nbsp;and&nbsp;phosphate&nbsp;in the blood and low levels of&nbsp;calcium&nbsp;in the blood).&nbsp;Symptoms may include kidney problems (weakness, shortness of breath, fatigue and confusion), heart problems (heart flutter with a faster or slower heartbeat), cramps, vomiting or diarrhea and tingling in the mouth, hands or feet.<\/li><\/ul>\n\n\n\n<p>If you experience any of the above symptoms after stopping treatment with Ontruzant, talk to your doctor and tell your doctor that you have previously been treated with Ontruzant.<\/p>\n\n\n\n<p>The side effects\u00a0listed below may occur at any time during treatment with Ontruzant, not just related to an\u00a0infusion.<\/p>\n\n\n\n<p><strong>Very common&nbsp;side effects&nbsp;of Ontruzant<\/strong>&nbsp;(may affect more than 1 in 10 people):<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>infection&nbsp;is<\/li><li>diarrhea<\/li><li>constipation<\/li><li>heartburn (&nbsp;dyspepsia&nbsp;)<\/li><li>fatigue<\/li><li>rash<\/li><li>chest pain<\/li><li>abdominal pain<\/li><li>joint pain<\/li><li>low levels of&nbsp;red blood cells&nbsp;and&nbsp;white blood cells&nbsp;(which help fight you&nbsp;infection&nbsp;), sometimes with fever<\/li><li>muscle pain<\/li><li>conjunctivitis&nbsp;(conjunctivitis of the eye)<\/li><li>watery eyes<\/li><li>nosebleeds<\/li><li>rinnsnuva<\/li><li>hair loss<\/li><li>tremors<\/li><li>hot flashes<\/li><li>dizziness<\/li><li>nail changes<\/li><li>weight loss<\/li><li>loss of appetite<\/li><li>insomnia (insomnia)<\/li><li>taste changes<\/li><li>decreased&nbsp;platelet count<\/li><li>bruises<\/li><li>numbness or tingling in the fingers and toes, which can sometimes spread to the rest of the arm or leg<\/li><li>redness&nbsp;, swelling or sores in the mouth and \/ or throat<\/li><li>pain, swelling,&nbsp;redness&nbsp;or tingling in the hands and \/ or feet<\/li><li>shortness of breath<\/li><li>headache<\/li><li>cough<\/li><li>vomiting<\/li><li>nausea<\/li><\/ul>\n\n\n\n<p><strong>Common\u00a0side effects\u00a0of Ontruzant<\/strong>\u00a0(may affect up to 1 in 10 people)<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table><tbody><tr><td>allergic reaction throat infection infection\u00a0you in the\u00a0bladder\u00a0and on the skin inflammation\u00a0of the chest inflammation\u00a0of the liver renal impact increased\u00a0muscle tone\u00a0or tension (hypertension)pain in arms and\/or legs itchy skin rashdrowsiness (\u00a0somnolence\u00a0)hemorrhoidsitchingleg cramps<\/td><td>dry mouth and skin dry eyessweatingfeeling of weakness and not feeling wellconcernDepressionasthmalung infection lung impact back pain neck painskeletal penance<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Uncommon&nbsp;side effects&nbsp;of Ontruzant<\/strong>&nbsp;(may affect up to 1 in 100 people):<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>deafness<\/li><li>lumpy rash<\/li><li>hissing \/ wheezing breathing<\/li><li>inflammation&nbsp;or scarring of the lungs<\/li><\/ul>\n\n\n\n<p><strong>Rare&nbsp;side effects&nbsp;of Ontruzant<\/strong>&nbsp;(may affect up to 1 in 1,000 people):<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>jaundice (yellowish discoloration of the skin or eyes)<\/li><li>anaphylactic reactions<\/li><\/ul>\n\n\n\n<p><strong>Other&nbsp;side effects&nbsp;reported with Ontruzant<\/strong>&nbsp;(frequency can not be calculated from the available data):<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>abnormal or impaired blood coagulation<\/li><li>high potassium levels<\/li><li>swelling or bleeding behind the eyes<\/li><li>shock<\/li><li>abnormal heart rhythm<\/li><li>respiratory distress<\/li><li>breathing problems<\/li><li>acute&nbsp;accumulation of fluid in the lungs<\/li><li>acutely&nbsp;narrower airways<\/li><li>abnormally low oxygen content in the blood<\/li><li>difficulty breathing when lying upright<\/li><li>liver damage<\/li><li>swelling of the face, lips and neck<\/li><li>kidney failure<\/li><\/ul>\n\n\n\n<p>During pregnancy:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>abnormally little amniotic fluid around the fetus in the womb<\/li><li>underdeveloped lungs of the fetus in utero<\/li><li>abnormal development of the kidneys of the fetus in the womb<\/li><\/ul>\n\n\n\n<p>Some of the\u00a0side effects\u00a0you are experiencing may be due to your underlying cancer.\u00a0If you are being treated with Ontruzant with cytotoxic drugs,\u00a0some of the\u00a0side effects\u00a0may also be due to the\u00a0cytotoxic drugs.<\/p>\n\n\n\n<p>If you get\u00a0any side effects, talk to your doctor, pharmacist, or nurse.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">How to store Ontruzant<\/h2>\n\n\n\n<p>Ontruzant should be stored by healthcare professionals at the hospital or clinic.<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>Keep this medicine out of the sight and reach of children.<\/li><li>Do not use this medicine after the expiry date which is stated on the outer carton and on the vial label after EXP.&nbsp;The expiration date is the last day of the specified month.<\/li><li>The unopened vial should be stored in a refrigerator (2 \u00b0 C-8 \u00b0 C).<\/li><li>The reconstituted solution must not be frozen.<\/li><li>Infusion solutions should be used immediately after&nbsp;reconstitution&nbsp;.&nbsp;If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 \u00b0 C to 8 \u00b0 C.<\/li><li>Do not use Ontruzant if you notice particles or discoloration before&nbsp;administration&nbsp;.<\/li><li>Medicines should not be disposed of via wastewater or household waste.&nbsp;Ask your pharmacist how to dispose of medicines no longer required.&nbsp;These measures will help to protect the environment.<\/li><\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Contents of the package and other information<\/h2>\n\n\n\n<h2 class=\"wp-block-heading\">Content declaration<\/h2>\n\n\n\n<ul class=\"wp-block-list\"><li>The active substance is trastuzumab.&nbsp;Each&nbsp;vial&nbsp;contains either:<ul><li>150 mg trastuzumab to be dissolved in 7.2 ml of water for&nbsp;injection&nbsp;, or<\/li><li>420 mg trastuzumab to be dissolved in 20 ml water for&nbsp;injection&nbsp;.<\/li><\/ul><\/li><li>The reconstituted solution contains approximately 21 mg \/ ml trastuzumab.<\/li><li>The other ingredients are L \u2011 histidine hydrochloride monohydrate, L \u2011 histidine, \u03b1, \u03b1-trehalose dihydrate, polysorbate 20.<\/li><\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">What the medicine looks like and contents of the pack<\/h2>\n\n\n\n<p>Ontruzant is a powder for concentrate for\u00a0intravenous\u00a0infusion, a solution provided in a glass\u00a0vial\u00a0with a rubber stopper containing either 150 mg or 420 mg of trastuzumab.\u00a0The powder is freeze-dried and white to slightly yellow.\u00a0Each carton contains 1\u00a0vial\u00a0of powder.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Marketing Authorization Holder and Manufacturer<\/h2>\n\n\n\n<p><strong>Marketing Authorisation Holder<\/strong><\/p>\n\n\n\n<p>Samsung Bioepis NL BV<br>Olof Palmestraat 10<br>2616 LR Delft<br>The Netherlands<\/p>\n\n\n\n<p><strong>Manufacturer<\/strong><\/p>\n\n\n\n<p>FUJIFILM Diosynth Biotechnologies Denmark ApS<\/p>\n\n\n\n<p>Biotek All\u00e9 1<\/p>\n\n\n\n<p>Hiller\u00f8d, 3400<\/p>\n\n\n\n<p>Denmark<\/p>\n\n\n\n<p>Samsung Bioepis NL BV<br>Olof Palmestraat 10<br>2616 LR Delft<br>The Netherlands<\/p>\n\n\n\n<p>Contact the representative of the marketing authorization holder to find out more about this medicine:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table><tbody><tr><td><strong>Belgium \/ Belgique \/ Belgien<\/strong>Organon BelgiumTel \/ Tel: 0080066550123(+32 2 2418100)dpoc.benelux@organon.com<\/td><td><strong>Lithuania<\/strong>Organon Pharma BV Lithuania atstovyb\u0117Tel .: + 370 52041693dpoc.lithuania@organon.com<\/td><\/tr><tr><td><strong>Bulgaria<\/strong>ORGANON (USA) B.V.&nbsp;-clone BulgariaTel: +359 2 806 3030info.bulgaria@organon.com<\/td><td><strong>Luxembourg \/ Luxemburg<\/strong>Organon BelgiumTel \/ Tel: 0080066550123(+32 2 2418100)dpoc.benelux@organon.com<\/td><\/tr><tr><td><strong>Czech Republic<\/strong>Organon Czech Republic sroTel .: +420 233 010 300dpoc.czech@organon.com<\/td><td><strong>Hungary<\/strong>Organon Hungary Kft.Tel .: +36 1 766 1963dpoc.hungary@organon.com<\/td><\/tr><tr><td><strong>Denmark<\/strong>Organon Denmark ApSTel: + 45 44 84 68 00info.denmark@organon.com<\/td><td><strong>Malta<\/strong>Organon Pharma BV, Cyprus branch.:\u0397\u03bb .: +356 22778116dpoc.cyprus@organon.com<\/td><\/tr><tr><td><strong>Germany<\/strong>MSD SHARP &amp; DOHME GMBHTel: 0800 673 673 673(+49 (0) 89 4561 2612)e-mail@msd.de<\/td><td><strong>The Netherlands<\/strong>NV OrganonTel .: 00800 66550123(+31 23 5153153)dpoc.benelux@organon.com<\/td><\/tr><tr><td><strong>Eesti<\/strong>Organon Pharma BV Estonian ROTel: +372 66 61 300dpoc.estonia@organon.com<\/td><td><strong>Norway<\/strong>Organon Norway ASTel: +47 24 14 56 60info.norway@organon.com<\/td><\/tr><tr><td><strong>Greece<\/strong>BIANE\u039e \u0391.\u0395:\u0397\u03bb: +30 210 80091 11Mailbox@vianex.gr<\/td><td><strong>Austria<\/strong>Merck Sharp &amp; Dohme Ges.mbHTel: +43 (0) 1 26 044msd-medizin@merck.com<\/td><\/tr><tr><td><strong>Spain<\/strong>Organon Salud, SLTel: +34 91 591 12 79<\/td><td><strong>Poland<\/strong>Organon Polska Sp.&nbsp;z ooTel: +48 22 105 50 01organonpolska@organon.com<\/td><\/tr><tr><td><strong>France<\/strong>Organon FranceTel: + 33 (0) 1 57 77 32 00<\/td><td><strong>Portugal<\/strong>Organon Portugal, Sociedade Unipessoal Lda.Tel: +351 218705500geral_pt@organon.com<\/td><\/tr><tr><td><strong>Croatia<\/strong>Organon Pharma dooTel: + 385 1 638 4530dpoc.croatia@organon.com<\/td><td><strong>Romania<\/strong>Organon Biosciences SRLTel: + 40 21 527 29 90info.romania@organon.com<\/td><\/tr><tr><td><strong>Ireland<\/strong>Organon Pharma (Ireland) LimitedTel: +353 (0) 1 2998700medinfo.ROI@organon.com<\/td><td><strong>Slovenia<\/strong>Organon Pharma BV, Oss, Ljubljana CompanyTel: + 386 1 300 10 80info.slovenia@organon.com<\/td><\/tr><tr><td><strong>Iceland<\/strong>Vistor hf.Phone: + 354 535 7000<\/td><td><strong>Slovak Republic<\/strong>Organon Slovakia sroTel: +421 2 44 88 98 88dpoc.slovakia@organon.com<\/td><\/tr><tr><td><strong>Italy<\/strong>Organon Italia SrlTel: +39 06 3336407dpoc.Italy@organon.com<\/td><td><strong>Finland \/ Finland<\/strong>Organon Finland OyPuh \/ Tel: +358 (0) 29 170 3520info.finland@organon.com<\/td><\/tr><tr><td><strong>.\u03a0\u03c1\u03bf\u03c2<\/strong>Organon Pharma BV, Cyprus branch.:\u0397\u03bb .: +357 22866730dpoc.cyprus@organon.com<\/td><td><strong>Sweden<\/strong>Organon Sweden ABTel: +46 8 502 597 00dpoc.sweden@organon.com<\/td><\/tr><tr><td><strong>Latvia<\/strong>Komrvalsts komersanta \u201cOrganon Pharma BV\u201d p\u0101rst\u0101vniec\u012bbaTel: + 371 66968876dpoc.latvia@organon.com<\/td><td><strong>United Kingdom (Northern Ireland)<\/strong>Samsung Bioepis NL BVOlof Palmestraat 10,2616 LR DelftThe Netherlands<\/td><\/tr><\/tbody><\/table><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Ontruzant contains the active substance trastuzumab, which is a monoclonal antibody . Monoclonal antibodies are attached to specific proteins or antigens . Trastuzumab is designed to bind selectively to an antigen called human epidermal growth factor receptor 2 ( HER2 ). HER2 is found in large amounts on the surface of certain cancer cells and then stimulates cell growth. When Ontruzant binds to HER2 , the growth of the cancer cells is stopped and it leads to their death.<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"cybocfi_hide_featured_image":"","footnotes":""},"categories":[2200,18526],"tags":[20020,13803,20016,20019,13800,13804,20017,13801,20018,13802],"class_list":["post-19813","post","type-post","status-publish","format-standard","hentry","category-medicines","category-o","tag-benefits-of-ontruzant","tag-benefits-of-trastuzumab","tag-ontruzant","tag-ontruzant-side-effects","tag-trastuzumab","tag-trastuzumab-side-effects","tag-what-is-ontruzant","tag-what-is-trastuzumab","tag-what-ontruzant-is-used-for","tag-what-trastuzumab-is-used-for"],"_links":{"self":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts\/19813","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/comments?post=19813"}],"version-history":[{"count":4,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts\/19813\/revisions"}],"predecessor-version":[{"id":19839,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts\/19813\/revisions\/19839"}],"wp:attachment":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/media?parent=19813"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/categories?post=19813"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/tags?post=19813"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}